Potential Implementation of Rabeprazole in prevention of Acidity in GIT: Short Statement

Authors

  • Ravi Kumar Panchawati Collegeof Pharmacy, Ghat Road Meerut.
  • Abhinay Gupta Kalka Institute for Research and Advanced Studies, Partapur Bypass, Meerut
  • Yogesh Kumar Yadav Neelkanth College of Pharmacy, Modipuram, UP.
  • Surjeet Singh School of Pharmaceutical Sciences, SDGI Global University, NH-9, Ghaziabad, U.P
  • Sachin Kumar Yadav School of Pharmaceutical Sciences, SDGI Global University, NH-9, Ghaziabad, U.P
  • Madhu Sharma Kalka Institute for Research and Advanced Studies, Partapur Bypass, Meerut
  • Vishu Jain Kalka Institute for Research and Advanced Studies, Partapur Bypass, Meerut
  • Abhimanyu Kumar Major SD Singhuniversity Faculty of Pharmacy, Fathegarh Farrukhabad.
  • Riddhi Malhotra Kalka Institute for Research and Advanced Studies, Partapur Bypass, Meerut
  • Parveen Kumar Kalka Institute for Research and Advanced Studies, Partapur Bypass, Meerut

DOI:

https://doi.org/10.22270/ajprd.v14i5.1858

Abstract

Rabeprazole is a proton pump inhibitor. Pharmacodynamic data show rabeprazole can achieve optimal acid suppression since the first administration and can maintain this advantage in the following days of therapy. Moreover, rabeprazole has the highest pKa (~ 5.0, the pH at which a drug becomes 50% protonated), and hence the molecule can be activated at higher pH levels much faster than other PPIs. Due to its peculiar catabolic pathway, ie, a prevalent metabolism through a non-enzymatic pathway, rabeprazole is less susceptible to the influence of genetic polymorphisms for CYP2C19, resulting in minor influences on its pharmacokinetics and pharmacodynamics. To prevent symptomatic relapse, on-demand strategy with rabeprazole 10 mg daily appears to be ideal, due to its rapidity of onset; results on NERD patients have documented its superiority over placebo. Continuous treatment, however, up to 5 years, seems to achieve better results than on-demand therapy, particularly in patients with esophagitis. It is debated whether in the latter halved doses (10 mg) are really equivalent to full dose (20 mg). Finally, rabeprazole achieves similar Helicobacter pylori eradication rates compared with omeprazole and pantoprazole when co-administrated with low or high doses of antibiotics (amoxicillin and clarithromycin). In addition, low doses of rabeprazole (10 mg/bid) may be effective in eradicating the pathogen.

 

Downloads

Download data is not yet available.

References

Adachi K, Hashimoto T, Hamamoto N, et al. 2013. Symptom relief in patients with refl2ux sophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J GastroenterolHepatol, 18:1392–8.

Adachi K, Katsube T, Kawamura A, et al. 2010. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment PharmacolTher, 14:1259-66.

Ando T, Kato H, Sugimoto N, et al. 2015. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences. Dig Dis Sci, 50:1625–31.

Archimandritis AJ, Nikolopoulou V, Kouklakis G, et al. 2005. Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study. Curr Med Res Opin, 21:603–10.

Barth J, Perdomo C, Sloan S. 1999. Rabeprazole maintains GERD healing in patients with Barrett’s esophagus. Am J Gastroenterol, 94:2579.

Bell NJ, Burget D, Howden CW, et al. 1992. Appropriate acid suppression for the management of gastro-oesophagealreflux disease. Digestion, 51(Suppl 1):59–67.

Besancon M, Simon A, Sachs G, et al. 1997. Sites of reaction of the gastric H,K-ATPase with extra cytoplasmicthiol reagents. J BiolChem, 272:22438–46.

Birbara C, Breiter J, Perdomo C, et al. 2000. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophagealreflux disease. Rabeprazole Study Group. Eur J GastroenterolHepatol, 12:889–97.

Bour B, Staub JL, Chousterman M, et al. 2005. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment PharmacolTher, 21:805–12.

Bruley Des Varannes S, Gharib H, Bicheler V, et al. 2004. Effect of lowdoserabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. Aliment PharmacolTher, 20:899–907.

Burget DW, Chiverton SG, Hunt RH. 1990. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology, 99:345–51.

Dickman R, Emmons S, Cui H, et al. 2005. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with noncardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment PharmacolTher, 22:547–55.

Dubois D, Hughes DA, Bodger K, et al. 2005. Economic analysis of ondemand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease. Pharmacoeconomics, 23:1031–41.

Farley A, Wruble LD, Humphries TJ. 2000. Rabeprazole versus ranitidine for the treatment of erosive gastro esophageal reflux disease: a doubleblind, randomized clinical trial. Raberprazole Study Group. Am J Gastroenterol, 95:1894–9.Fass R, Ofman JJ. 2002.

Gastroesophageal reflux disease: should we adopt a new conceptual framework? Am J Gastroenterol, 97:1901–9. Feldman M, Burton ME. 1990. Histamine H2-receptor antagonists. N Engl J Med, 323:1672–80.

Fletcher J, Wirz A, Young J, Vallance R, McColl KE. 2001. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology, 121:775–83.

Fock KM, Teo EK, Ang TL, et al. 2005. Rabeprazolevs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, doubleblind study in urban Asia. World J Gastroenterol, 11:3091–8. Fuhr U, Jetter A. 2002.

Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie, 57:595–601.

Furuta T, Shirai N, Sugimoto M, et al. 2005. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug MetabPharmacokinet, 20:153–67.

Gambaro C, Bilardi C, Dulbecco P, et al. 2003.Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a prelimary study. Dig Liv Dis, 35:763–7.

Gardner JD, Gallo-Torres H, Sloan S, et al. 2003. The basis for the decreased response to proton pump inhibitors in gastro-oesophagealreflux disease patients without erosive oesophagitis. Aliment PharmacolTher, 18:891–905.

Gerson LB, Shetler K, Triadafilopoulos G. 2005. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett’s oesophagus. Dig Liv Dis, 37:651–8.

Warrington S, Baisley K, Boyce M, et al. 2002. Effects of rabeprazole 20 mg, or esomeprazole 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment PharmacolTher, 16:1301–7. Williams MP, Sercombe J, Hamilton MI, et al. 1998.

A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment PharmacolTher, 12:1079–89.

Published

2026-10-15

How to Cite

Ravi Kumar, Abhinay Gupta, Yogesh Kumar Yadav, Surjeet Singh, Sachin Kumar Yadav, Madhu Sharma, … Parveen Kumar. (2026). Potential Implementation of Rabeprazole in prevention of Acidity in GIT: Short Statement. Asian Journal of Pharmaceutical Research and Development, 14(5), 154–158. https://doi.org/10.22270/ajprd.v14i5.1858